MeiraGTx Holdings PLC (NASDAQ:MGTX) has earned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a strong buy rating.
Brokers have set a 1-year consensus price objective of $33.00 for the company, according to Zacks. Zacks has also assigned MeiraGTx an industry rank of 62 out of 256 based on the ratings given to its competitors.
Several research analysts have recently commented on the stock. Barclays restated a “hold” rating on shares of Mettler-Toledo International in a research note on Wednesday, May 15th. Chardan Capital set a $25.00 price target on shares of Tocagen and gave the stock a “buy” rating in a research note on Tuesday, May 14th. Finally, Zacks Investment Research upgraded shares of Hudson Technologies from a “sell” rating to a “hold” rating in a research note on Wednesday, May 29th.
Shares of MGTX traded down $0.33 during mid-day trading on Friday, hitting $29.07. 1,265 shares of the company’s stock were exchanged, compared to its average volume of 213,611. The firm’s fifty day simple moving average is $23.73. MeiraGTx has a twelve month low of $7.98 and a twelve month high of $30.23. The firm has a market capitalization of $981.60 million and a PE ratio of -6.64. The company has a current ratio of 6.96, a quick ratio of 6.96 and a debt-to-equity ratio of 0.02.
MeiraGTx (NASDAQ:MGTX) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($0.62) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.64) by $0.02. The business had revenue of $0.79 million for the quarter.
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases.
See Also: Momentum Indicators
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.